Document is current

Article History

Received: 1 August 2025

Accepted: 27 January 2026

First Online: 3 February 2026

Declarations

:

: The trials included in this study received approval from the local institutional ethics committee of the Hospital of Prato and by the Area Vasta Toscana Centro and local Ethics Committee (CEAVC 15108; CEAVC 11252), in accordance with Helsinki Declaration. Written informed consent was prospectively obtained from all patients participating in these trials.

: Not applicable.

: Authors declare that they have no competing interests related to this work. Out of this work, ER reports honoraria from Eisai; travel grants from Pfizer, Gilead Sciences; LM reports Honoraria from Pfizer, Novartis, Seagen; consulting or advisory role from Pfizer, Novartis, Seagen, Roche, Menarini Group; research funding from Pfizer, Novartis; travel, accommodations, expenses from Roche, Janssen, Gilead Sciences, Menarini Group; LB reports personal financial interests (Honoraria, consultancy or advisory role) from Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Menarini, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, SeaGen; institutional financial interests from Celgene, Genomic Health, Novartis; travel grant from AstraZeneca, Daiichi-Sankyo. The remaining authors declare that they have no competing interests.